Journal
CURRENT CANCER DRUG TARGETS
Volume 19, Issue 4, Pages 277-284Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009618666180817095331
Keywords
Anticancer drugs; animal toxicological studies; animal models; starting doses; preclinical testing; toxicological studies
Categories
Funding
- Ministry of Science and Technology of China [2015CB931804]
- National Natural Science Foundation of China [81273548]
Ask authors/readers for more resources
Background: One of the main reasons for most of the anticancer drugs to fail in the late preclinical testing and early clinical trials is the differences in drug effects observed from animals and patients, and the challenge has been to find a balance to reduce the inherent differences from species. Objective: Predicting safe starting doses and dosing schedules for human clinical trials is the main purpose of toxicological studies of anticancer drugs. Methods: Relevant information and data were assimilated from manuscripts, congress publications, and online sources. Results: We systematically overview the cons and pros of animal models and briefed the ways to determine human clinical starting doses derived from animal toxicological studies for anticancer drugs. Conclusion: This information helps smart select the suitable predictive model for anti-cancer drugs with the different mechanisms and emphasized the pharmaceutical challenges behind and ahead.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available